血清嗜酸性粒细胞对晚期黑色素瘤患者免疫治疗疗效的预测作用。
Prognosticating role of serum eosinophils on immunotherapy efficacy in patients with advanced melanoma.
机构信息
Department of Medical Oncology, Cancer Centre of Southeastern Ontario, Kingston, Ontario K7L 2V7, Canada.
Queen's University, Kingston, Ontario K7L 2V7, Canada.
出版信息
Immunotherapy. 2021 Feb;13(3):217-225. doi: 10.2217/imt-2020-0265. Epub 2020 Nov 26.
To evaluate serum eosinophilia (≥500 peripheral eosinophil counts/microliter) in prognosticating immunotherapy (IO) efficacy. A retrospective study of 86 patients with advanced melanoma on PD-1 inhibitors. Eosinophilia-on-IO was an independent prognosticating factor for median OS (HR :0.223; 95% CI: 0.088-0.567; p = 0.002). 'Late eosinophilia' (≥1 year from IO start date) group had better median OS (31.9 vs 24.1 vs 13.0 months; p = 0.002) when compared with 'early eosinophilia' (<1 year from IO start date) and 'no eosinophilia' groups, respectively. Eosinophilia-on-IO and its timing were associated with better IO efficacy in patients with advanced melanoma. Our findings provided insights on potential therapeutic benefit of inducing eosinophilia at certain interval time to obtain a longer durable immunotherapy response.
评估血清嗜酸性粒细胞增多症（外周嗜酸性粒细胞计数≥500/微升）对免疫治疗（IO）疗效的预测作用。一项回顾性研究纳入了 86 例接受 PD-1 抑制剂治疗的晚期黑色素瘤患者。嗜酸性粒细胞增多症是影响 IO 患者总生存期（OS）的独立预后因素（HR：0.223；95%CI：0.088-0.567；p=0.002）。与“早期嗜酸性粒细胞增多症（IO 开始后<1 年）”和“无嗜酸性粒细胞增多症”组相比，“晚期嗜酸性粒细胞增多症（IO 开始后≥1 年）”组的中位 OS 更长（31.9 个月 vs 24.1 个月 vs 13.0 个月；p=0.002）。嗜酸性粒细胞增多症及其出现时间与晚期黑色素瘤患者的 IO 疗效改善相关。我们的研究结果为在特定时间间隔诱导嗜酸性粒细胞增多以获得更长时间的持久免疫治疗反应提供了潜在的治疗益处。
Zotero 插件